BAC transgenic mice to study the expression of P2X2 and P2Y1 receptors

Marcus Grohmann1,2 · Michaela Schumacher3 · Janka Günther3 · Stefan M. Singheiser3 · Tanja Nußbaum3 · Florian Wildner4 · Zoltan Gerevich4 · Ronald Jabs5 · Daniela Hirnet6 · Christian Lohr6 · Peter Illes1 · Günther Schmalzing3 · Heike Franke1 · Ralf Hausmann3

Received: 16 November 2020 / Accepted: 19 April 2021 / Published online: 28 May 2021
© The Author(s) 2021

Abstract
Extracellular purines are important signaling molecules involved in numerous physiological and pathological processes via the activation of P2 receptors. Information about the spatial and temporal P2 receptor (P2R) expression and its regulation remains crucial for the understanding of the role of P2Rs in health and disease. To identify cells carrying P2X2Rs in situ, we have generated BAC transgenic mice that express the P2X2R subunits as fluorescent fusion protein (P2X2-TagRFP). In addition, we generated a BAC P2Y1R TagRFP reporter mouse expressing a TagRFP reporter for the P2RY1 gene expression. We demonstrate expression of the P2X2R in a subset of DRG neurons, the brain stem, the hippocampus, as well as on Purkinje neurons of the cerebellum. However, the weak fluorescence intensity in our P2X2R-TagRFP mouse precluded tracking of living cells. Our P2Y1R reporter mice confirmed the widespread expression of the P2RY1 gene in the CNS and indicate for the first time P2RY1 gene expression in mouse Purkinje cells, which so far has only been described in rats and humans. Our P2R transgenic models have advanced the understanding of purinergic transmission, but BAC transgenic models appeared not always to be straightforward and permanent reliable. We noticed a loss of fluorescence intensity, which depended on the number of progeny generations. These problems are discussed and may help to provide more successful animal models, even if in future more versatile and adaptable nuclease-mediated genome-editing techniques will be the methods of choice.

Keywords P2X2 receptor · P2Y1 receptor · Brain · TagRFP · BAC transgenic mice

Marcus Grohmann completed a master’s degree in microbiology, immunology and embryology from Friedrich–Alexander University Erlangen, Germany and received his PhD from the University of Leipzig, Germany in the field of molecular neuroscience. During post-doctoral studies at Monash University, Australia he investigated the molecular mechanisms how obesity affect tumour cells and the immune system to promote the development of cancer before returning to Germany in 2018 focusing on innovations in infection control.
Introduction

The functions of the purine nucleotide ATP as a potent extracellular neurotransmitter via the activation of the P2 receptor (P2R) family is well-established, and virtually every tissue expresses P2Rs, indicating that ATP and related purines act as a common transmitter in almost all tissues and organs [1]. Information about the precise distribution of specific receptor subtypes on specific cells such as neurons or glial cells and their regulation in disease models remains crucial for the understanding of the role of P2R-mediated cellular processes in health and disease (comprehensively reviewed in [1]).

P2XRs are homo- and heterotrimeric cation-selective ligand-gated ion channels, which open upon extracellular binding of ATP and thus act as electrical “cell surface ATP sensors” [2]. P2XRs are involved in a variety of physiological functions throughout the body, including neuroeffector transmission from neuron to muscle, neurotransmission from neuron to neuron, bladder function, and breathing or taste perception (for review see [3–5]).

The P2X2R is one of the most widely expressed P2XRs in the body. P2X2R subunits have been found in the central (CNS) and peripheral (PNS) nervous systems [1], with high expression levels in the cerebral cortex, basal ganglia, diencephalon, mesencephalon, cerebellum, medulla oblongata, olfactory bulb, and dorsal horn of the spinal cord [6] and the inner ear [5]. Despite its widespread CNS expression, P2X2 knockout mice do not exhibit a strong CNS phenotype in terms of general excitability and sensory and motor function [4, 7]. Possible explanations are that P2X2Rs are of secondary importance for the healthy brain or that other genes functionally compensate their deletion. The involvement of P2X2R subunit-containing receptors in sensory transmission has been confirmed in acute and chronic pain models performed with P2X2R subunit knockout mice [7]; for review, see [8].

P2YRs are a family of G protein-coupled receptors [9], which are known to be expressed in almost all mammalian tissues (for review see [9]). P2YRs mediate responses such as vasodilation, blood clotting/platelet aggregation, and immune response [9]. Clopidogrel, a blockbuster drug that has been used for thrombosis prophylaxis since 1996, was found in 2001 to exert its antithrombotic effects by irreversibly blocking the P2Y12R on platelets through an active metabolite formed in the liver [10]. Other P2YRs are also common targets in drug development [9, 11]. In the CNS, P2Y1Rs are found on neurons, e.g., of the hippocampus, basal ganglia, cerebellum, and spinal cord. For instance, P2Y1Rs are thought to be involved in proliferation and migration processes of neuronal progenitor cells, in brain development and regeneration, and in sensory neurotransmission and pain perception [12–17].

Taken together, P2X2- and P2Y1Rs are crucially involved in neuronal and glial physiology. There is also accumulating evidence indicating a role of these receptors under diverse pathophysiological conditions and disorders of the CNS [18]. In particular, there is converging evidence from electrophysiological, genetic, and pharmacological studies supporting an important role for P2X2-, P2X3-, and P2Y1Rs in nociception [8, 19, 20]. Accordingly, P2X/PYRs have attracted widespread interest as novel therapeutic targets (for recent reviews see [5, 9]), which has led to the “Transition of purinergic signaling to drug discovery” [21].

To facilitate the targeting of neurons or other cells carrying P2X2Rs or P2Y1Rs in animal models of disorders of the CNS, we have generated transgenic BAC mice, which express these subunits as fluorescent fusion proteins (P2X2-TagRFP) or TagRFP as a reporter for P2Y1R expression, each under the control of their own promoters of the P2RX2 or P2RY1 gene, respectively. These animals should be used to (i) allow for a comprehensive microscopic mapping of the distribution of P2X2Rs and P2Y1Rs in mice and (ii) guide the identification of neurons for patch-clamp recordings or Ca2+ imaging experiments.

It should be noted here that in recent years, the methods for generation of transgenic mice have been developed very rapidly. In particular, the CRISPR/Cas technology has made targeted genetic modifications possible with the highest efficiency and in short order. However, the CRISPR/Cas technology was not available at the time when the present study was initiated. At that time, a large number of reports were available showing that BAC transgenic mice are valuable tools to map the tissue-specific gene expression pattern (for instance, see [22]). One of the best known projects is the Gene Expression Nervous System Atlas (GENSAT) project at the Rockefeller University (New York), which aims to map the expression of genes in the CNS of the mouse, using transgenic mouse (and in situ hybridization) techniques [23]. For these reasons, we have used the then established methods of BAC transgenesis.

Material and methods

Chemicals

Standard chemicals or products for immunohistochemistry were purchased from Sigma-Aldrich/Merck or Invitrogen/ThermoFisher, respectively.

P2X receptor expression in Xenopus laevis oocytes

The cDNA encoding the mouse P2X2 subunit was a generous gift from T. Koshimizu (Faculty of Pharmaceutical Sciences, Kyoto University, Japan). After subcloning of the coding sequence into the oocyte expression vector pNKS...
affinity tag mutations (StrepII- and His6-tag) was introduced by site directed-mutagenesis following the QuikChange protocol (Stratagene, La Jolla, CA). The TagRFP coding sequence was cloned from the pTagRFP-N vector (Evrogen, Moscow, Russia) into the open reading frame by introduced HindIII and MfeI restriction sites to generate the mP2X2-StrepII-His-TagRFP oocyte expression construct. All constructs were verified by restriction analysis and nucleotide sequencing. Capped cRNAs were synthesized and injected into collagenase-defolliculated X. laevis oocytes using a Nanoliter 2000 injector (WPI, Sarasota, FL, USA) as described previously [24, 25]. Oocytes were cultured at 19 °C in sterile oocyte Ringer’s solution (ORi: 90 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM Hepes, pH 7.4) supplemented with 50 μg/ml gentamycin (Sigma-Aldrich, Taufkirchen, Germany).

**Protein labeling, purification, and PAGE**

cRNA-injected oocytes were metabolically labeled by overnight incubation with l-[35S]methionine and, just before protein extraction additionally surface-labeled with Cy5-NHS ester (50 μg/ml, GE Healthcare Biosciences), an amine-reactive, membrane-impermeant fluorescent dye [24, 26]. His-tagged proteins were purified by Ni-NTA agarose (Qiagen, Hilden, Germany) chromatography from digitonin (1%, w/v) extracts of oocytes and analyzed by blue native PAGE (BN-PAGE; polyacrylamide gel electrophoresis) as detailed previously [24, 27]. If indicated, samples were treated before BN-PAGE for 1 h at 37 °C with 0.1% (w/v) sodium dodecyl sulfate (SDS) to induce partial dissociation of mP2X2 complexes. The BN-PAGE gels were destained before fluorescence imaging as detailed previously [28]. The Cy5-labeled plasma membrane-bound proteins and the TagRFP-tagged mP2X2 subunits were visualized by a Typhoon 9410 fluorescence scanner (GE Healthcare).

Figures were prepared by using ImageQuant TL v2005 (Amersham) for contrast adjustments, Adobe Photoshop CS 8.0 for level adjustment and cropping, and Microsoft PowerPoint 2000 for lettering.

**Cell cultures**

All chemicals and media for cell culture were purchased from Invitrogen/ThermoFisher.

(i) **HEK cell cultures:** The propagation of human embryonic kidney cell line 293 (HEK293) was performed according to the American Type Culture Collection (ATCC) in Eagle’s minimal essential medium (MEM; Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin in a humidified atmosphere with 5% CO2/95% air at 37 °C. Splitting of the cells was realized two or three times a week.

(ii) **Isolation and culture of mouse dorsal root ganglion cells:** The mice were killed under CO2, decapitated, and dorsal root ganglia (DRG) were removed aseptically from all levels of the spinal cord. After enzymatic and mechanical dissociation described previously [29], cells were cultured onto poly-L-lysine-coated glass coverslips in Dulbecco’s MEM containing 35 mM glucose, 2.5 mM L-glutamine, 15 mM HEPES, 50 μg/ml gentamicin, and 5% (FBS), supplemented with 10 μg/ml insulin, 5.5 μg/ml transferrin, and 5 ng/ml selenium. The cells were usually studied after 2–4 days in culture under 5% CO2 at 37 °C.

(iii) **Mixed astroglial-neuronal hippocampal cell cultures:** The preparation was performed as previously described [30]. In short, Wistar rat fetuses at gestational day 18 or from newborn rats at postnatal day 1 were used. The hippocampi were dissected, minced, and pooled in ice-cold (4 °C) HBSS (Life Technologies, Carlsbad, USA). Tissue samples were then dissociated in 1.5 ml of 0.05% trypsin (Invitrogen) in HBSS for 5 min at 37 °C. Enzymatic digestion was stopped by trypsin inhibitor (0.7 mg/ml; Sigma-Aldrich, Deisenhofen, Germany) added to a 1:1 mixture of Dulbecco’s modified Eagle medium (DMEM; Gibco, ThermoFisher Scientific Inc., USA) containing 36 mM D(+)-glucose, 15 mM HEPES (pH 7.4 with NaOH) plus 50 μg/ml gentamicin, and neurobasal medium (NBM; Gibco) mixed with B27 supplements (Gibco) containing 0.5 mM L-glutamine. After gentle trituration and centrifugation (80×g for 5 min; repeated three times in total, separated by washout periods), the remaining cell pellet was re-suspended in the culture medium of the above composition. The final cell suspension was then seeded onto glass coverslips at a plating density of 4 × 103/cm². Cultures were maintained in 2 ml of the culture medium in wells at 37 °C in a humidified atmosphere of 5% CO2 in air.

**Transient expression in HEK293 cells and patch-clamp electrophysiology**

The mP2X2-StrepII-His coding sequence was subcloned from the pNKS vector into the pTagRFP-N vector by introduced HindIII/BamHI restriction sites. The resulting mP2X2-StrepII-His-TagRFP-pTagRFP-N plasmid was verified by restriction analysis and nucleotide sequencing. HEK293 cells were transfected by lipofectamine 2000
rate the DNA quality independently. PCR conditions were 94 °C for 30 s, 60 °C for 45 s, and 72 °C for 60 s, operating for 32 cycles.

**Generation of the transgenic P2Y$_2$R mouse line C57BL/6 J-Tg(RP23-452G4P2RY1-TagRFP)**

**Identification of a suitable BAC clone**

Using the ENSEMBL database (http://www.ensembl.org), the BAC clone RP23-452G4 from the mouse C57BL/6 BAC library RPCI-23 [31] was identified to contain the entire P2RY1 gene. According to this database, BAC clone 452G4 is 168, 946-bp long (base 60, 882, 608–61, 051, 254 of chromosome 3) and contains the entire P2RY1 gene (from base 61, 002, 795 to 61, 008, 979) with its protein-coding region from base 61, 003, 433 to 61, 004, 560 and an additional 120 kb and 42 kb of DNA flanking the 5’ end of exon 1 and the 3’ end of exon 2, respectively. The BAC clone 452G4 (in the pBACe3.6 vector) present in *E. coli* DH10B bacteria was purchased from ImaGenes (Berlin, Germany). According to the National Center for Biotechnology Information (NCBI) clone database, this BAC clone (CloneDB ID: 588,612) contained no other entire genes. The presence of the entire P2RY1 protein-coding sequence within BAC 452G4 was verified by polymerase chain reaction (PCR) and subsequent nucleotide sequencing analysis (MWG Biotech, Ebersberg, Germany) of exon 1.

**Generation of the targeting cassette**

A TagRFP-pA-FRT-PGK-gb2-Kan-FRT-cassette was generated via conventional and PCR-mediated cloning techniques using the pTagRFP-N vector (Evrogen; Moscow, Russia) and the FRT-PGK-gb2-Kan-FRT cassette of the Quick & Easy Conditional Knockout Kit (FRT/FLPe) (Gene Bridges GmbH; Heidelberg, Germany) as templates. The entire cassette was verified by nucleotide sequencing (MWG Biotech, Ebersberg, Germany).

For targeting the cassette to the region directly 5′ of the P2RY1 gene of the BAC clone 452G4, the verified TagRFP-pA-FRT-PGK-gb2-Kan-FRT-cassette was amplified by specifically designed PCR primers with 50 bp homology to the region directly 5′ of the start codon and the first 50 bp of the protein-coding sequence of the P2RY1 gene, respectively.

**Modification of the BAC clone and generation of the C57BL/6 J-Tg(RP23-452G4P2RY1-TagRFP) reporter mouse**

Insertion of the amplified TagRFP-pA-FRT-PGK-gb2-Kan-FRT selection cassette directly 5′ of the start codon of the P2RY1 coding sequence and subsequent removal of the
FRT-PGK-gb2-Kan-FRT cassette was performed via Red/ET and FLP-mediated homologous recombination, respectively, in *E. coli* DH10B cells containing the BAC clone 452G4 using the Quick & Easy Conditional Knockout Kit (FRT/FLPe) (Gene Bridges) according to the manufacturer’s protocol.

To verify proper recombination and to exclude the presence of major undesired recombination events after each round of homologous recombination, restriction analysis using the Spel site present in the FRT-PGK-gb2-Kan-FRT cassette and 1% agarose gel electrophoresis was performed. At the end of the BAC modification process, the modified region of the BAC clone was verified by nucleotide sequencing.

For pronuclear injections, BAC DNA was purified by the BAC 100 Kit according to the manufacturer’s protocol (Macherey–Nagel, Düren, Germany). The concentration of the isolated BAC DNA was determined with the Nanodrop 1000 spectrometer (ThermoFisher Scientific, USA), and 20 μg BAC DNA was linearized via the PI-SceI site present in the pBACe3.6 vector by the homing endonuclease PI-SceI (New England Biolabs, Ipswich, USA). The linear BAC DNA was dialyzed overnight against injection buffer (5 mM Tris/HCl, 0.1 mM EDTA, pH 7.6) and verified by sequence analysis (MWG Biotech).

Pronuclear injection of the modified BAC DNA (3 ng/l) into fertilized oocytes of C57BL/6J mice, implantation into pseudopregnant C57BL/6 J females, and breeding of the founder mice were performed at the transgenic core facility of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) (Dresden, Germany) as described previously [33]. PCR analysis for the presence of TagRFP revealed nine transgenic founder mice, of which eight showed germline transmission of the transgene. The breeding of the C57BL/6J-Tg(RP23-452G4P2RY1-TagRFP) line was heterozygous with respect to the transgene.

**DNA analysis**

Genomic DNA from tail biopsies was extracted using REDExtract-N-Amp Kit (Sigma-Aldrich). The presence of the integrated BAC sequence was determined by via multiplex-PCR with the following primer pairs, amplifying a 460-bp DNA fragment of the transgene (5′-TGG GTG TGG TTG ATG AAG G-3′ and 5′-ACC AGC ATA TGG GAC AAA GG-3′) and a 1 kb fragment of the actin beta gene as an internal control (5′-GAT GAC GAT ATC GCT GCG CTG GTC G-3′ and 5′-GCC TGT GGT ACG ACC AGA GGC ATA CAG-3′). PCR conditions were 94 °C for 30 s, 60 °C for 45 s, and 72 °C for 60 s, operating for 32 cycles.

**Mice breeding (both mice lines)**

C57BL/6 J mice were bred at the Institute of Laboratory Animal Science of the RWTH Aachen and at the animal house of the Rudolf Boehm Institute of Pharmacology and Toxicology, University of Leipzig (both, Germany). All animals were kept at a standard 12 h light–dark cycle and supplied with food and water ad libitum under defined pathogen-free conditions. All transgenic lines were bred heterozygous.

Animal experiments were in compliance with the European Union legislation (Directive 86/609/EEC), approved by the Committee of Animal Care and Use of the relevant local governmental body and in accordance with the European Federation of European Laboratory Animal Science Associations (FELASA) standards and were approved by the relevant regulatory authorities (Leipzig: T36/12; T21/13; T05/16; Aachen: *Xenopus laevis* oocytes for heterologous protein expression: 9.93.2.10.44.07.104; mice: 10,857 A4).

**Visualization/immunolabeling/cell imaging of transgenic and control mice**

**Immunolabeling**

(i) *Living cells*

For labeling of living cells, cultures (e.g., DRG neurons of P2X2 mouse line, see (ii)) were washed twice with PBS (pH 7.4) at room temperature. Unspecific binding was blocked with 10% FBS in HBSS at 37 °C for 30 min. To identify non-peptidergic neurons in the culture 30 min incubation with 1 μg/ml biotinylated *Griffonia simplicifolia* isolecitin-B4 (GSI-B4; Sigma) was performed at 37 °C. Cells were washed three times with PBS, before carbocyanine Cy5-labeled streptavidin was applied for 30 min at 37 °C in HBSS with 10% fetal calf serum (FCS), respectively. After washing the cells with PBS at room temperature, 1 μg/ml Hoechst 33342 in PBS for 5 min was used to visualize the nuclei. PBS was replaced by HEPES buffered solution (HBS, pH 7.4) containing 155 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, 10 mM glucose, and 10 mM HEPES for imaging.

(ii) *DRG primary cultures*

Cells were fixed with a 2% paraformaldehyde (PFA) solution in PBS (pH 7.4) for 10 min at 4 °C and washed twice with PBS. Unspecific binding sites were blocked for 30 min by 10% fetal goat serum and 1% bovine serum albumin (BSA) in PBS with 0.05% Triton X100, to permeabilize the cell membranes. To enhance the signal of the fluorescence protein, a polyclonal rabbit antibody against TagRFP (Evrogen, Moscow, Russia) was used in combination with Cy2-labeled goat anti-rabbit IgG (Jackson ImmunoResearch Inc., PA, USA).
(iii) Mixed astroglial-neuronal hippocampal cell cultures (of P2RY1-TagRFP mice)

At DIV 8, a scratch lesion diagonally through the mixed hippocampal culture using a pipette tip was performed. At DIV 10, the cultures were washed with PBS and then treated with ice-cold 2% PFA in PBS (pH 7.4) for 10 min at 4 °C and washed twice with PBS.

Unspecific binding sites were blocked for 30 min by blocking buffer (10% FBS and 1% BSA in PBS with 0.05% Triton X100) at room temperature. For the immunolabeling procedure, cells were incubated with the primary antibody (mouse anti-GFAP, 1:1000, Sigma-Aldrich) overnight at 4 °C. After washing in PBS, subsequent incubation with secondary antibody (donkey anti-rabbit IgG conjugated to Cy2, 1:500; Jackson ImmunoResearch) and goat or donkey anti-mouse IgG conjugated to Cy5 (dilution 1:500; Jackson ImmunoResearch) was added for 5 min before the end of this incubation period.

(iv) Slices/sections from mice

The mouse tissues of young and adult mice were fixated by transcardial perfusion under thiopental sodium anesthesia with 4% PFA solution in PBS (pH 7.4). After removal of the brain, the subsequent postfixation for 1 h was performed in the same solution.

Different kinds of tissue slices were used: (a) cryosections and (b) free-floating slices.

(a) Cryo slices (18–20 µm): The tissues were cryoprotected in 30% sucrose in PBS (pH 7.4). Coronal sections were sliced with a cryostat (Leica, CM3050S, Wetzlar, Germany) using tissue freezing medium von Jung (Leica Instruments GmbH, Nussloch, Germany). The cryoprotectant was removed by three wash steps in PBS, followed by postfixation with cold methanol. Tyramide signal amplification (TSA) used for P2X2R mouse with 0.3% H2O2. Ten percent non-fat dry milk in PBS (pH 7.4) with 0.2% Triton X100 and avidin blocking solution (Avidin/Biotin Blocking, Vector Labs, Burlingame, USA) was used to saturate non-specific binding sites. Followed incubation with primary antibody against TagRFP was performed in PBS solution with 0.2% Triton X100 with 1% normal goat serum (NGS) and biotin blocking solution. Biotin was added in a next step by biotin-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Inc., PA, USA). After coupling of streptavidin-HRP (NEN Life Science Products Inc., Boston, USA), biotin-conjugated tyramide solution (NEN Life Science Products Inc., Boston, USA) was deployed prior incubation with Cy5-labeled streptavidin.

(b) Free-floating slices (50 µm): After pericardial perfusion fixation, the brains were cut into 50 µm slices using a vibratome (Leica, Typ VT 1200S, Nussloch, Germany) and collected and stored at 4 °C in PBS.

For the immunolabeling procedure, slices were rinsed three times with PBS for 5 min to remove the cryoprotectant compound and were subsequently incubated with a blocking buffer (10% NGS, 0.2% BSA in PBS) for 60 min at room temperature. After the incubation with primary antibodies overnight at 4 °C, subsequent incubation with secondary antibodies followed for 2 h at room temperature.

For expression analysis and cell identification, the following antisera were used: polyclonal rabbit anti-TagRFP (AB233, dilution 1:2000; Evrogen, Moscow, Russia), monoclonal mouse anti-microtubule associated protein-2 (MAP2) (MAB3418, dilution 1:1000; Merck Millipore, Darmstadt, Germany), monoclonal mouse anti-neuron-specific nuclear protein (NeuN) (MAB377, dilution 1:2000, Merck Millipore, Darmstadt, Germany), and monoclonal mouse anti-glial fibrillary acidic protein (GFAP) (WH0002670M1 dilution 1:1000; Sigma-Aldrich).

For primary antibody detection polyclonal goat or donkey anti-rabbit IgG conjugated to Cy2 (dilution 1:500; Jackson ImmunoResearch) and goat or donkey anti-mouse IgG conjugated to Cy5 (dilution 1:500; Jackson ImmunoResearch) were used. For nuclear staining, Hoechst 33342 (Hoe, 10 µg/ml; Molecular Probes, Leiden, Netherlands) was added for 5 min, and residual dye was removed by a final PBS washing step. After staining procedure, the slices were mounted onto glass slides prior to imaging. When slices were incubated in PBS without the primary antibody, or with primary antibody which had been pre-absorbed with peptide antigen for 1 h before use, no immunofluorescence was observed.

All stained sections were dehydrated in a series of graded ethanol, processed through n-butylacetate and coversipped with Entellan (Merck, Darmstadt, Germany) or RotiMount FluorCare (Roth, Karlsruhe, Germany).

Confocal microscopy/fluorescence microscopy

All slides were visualized by using a (i) Zeiss Axiovert 200 M fluorescence microscope equipped with an HBO 150 lamp or (ii) a confocal laser scanning microscope (cLSM 510 Meta, Zeiss, Oberkochen, Germany) using excitation wavelengths of 488 nm (argon, yellow-green Cy2/Alexa 488-immunofluorescence labeling), 543 nm (helium/neon1, red fluorescence), and 633 nm (helium/neon2, blue Cy5/ DyLight-labeling). An ultraviolet laser (362 nm) was used.
to illustrate the blue-cyan Hoechst 33342 auto-fluorescence. Color coding of the Cy5-immunofluorescence to allow optimal illustration of all labeled structures was performed.

**Results**

**P2X2R transgenic mouse model**

To facilitate the morphological identification and functional characterization of cells expressing the P2X2R, we generated C57BL/6 J-Tg(RP23-333M22P2X2-StrepHis-TagRFP) BAC-transgenic mice expressing the P2X2R protein fused to TagRFP under control of the regulatory elements of the P2RX2 gene.

We used the red fluorescence protein TagRFP, a monomeric derivative of eqFP578 [34], which is characterized by high brightness, complete chromophore maturation, prolonged fluorescence lifetime, and high pH-stability [35]. These properties make TagRFP to an excellent tag for protein localization studies and fluorescence resonance energy transfer applications.

For the generation of the C57BL/6 J-Tg(RP23-333M22P2X2-StrepHis-TagRFP) transgenic mouse model, which expresses a fusion protein consisting of the mP2X2R, affinity tags, and TagRFP, extensive preliminary studies were necessary: It was crucial to ensure that the fusion of the affinity tags (His6- and StrepII-tag) as well as the TagRFP would not affect protein expression, trimeric assembly, function, and plasma membrane expression. As an example for this studies, Fig. 1a and b show different constructs of the mP2X2R with N- or C-terminal fused affinity tags and C-terminal fused TagRFP expressed in Xenopus laevis oocytes, purified in non-denatured form by Ni2+-affinity chromatography, and separated by Blue-native gel electrophoreses (BN-PAGE) in their native forms. After staining of the intact oocytes with the membrane-impermeant Cy5 dye, the plasma membrane fraction of the indicated constructs is

---

**Fig. 1** Plasma membrane expression, oligomeric assembly, and function of affinity- and TagRFP-tagged mP2X2 receptors. a, b For biochemical analysis, X. laevis oocytes expressing the indicated mP2X2 subunit tagged at the N-terminus (N) or C-terminus (C) with a His- (H), StrepII (S), or TagRFP-tag (R) were surface labeled with the membrane-impermeant fluorescent Cy5 dye before protein purification. The indicated proteins were purified under non-denaturing conditions from X. laevis oocytes by Ni2+-NTA chromatography, resolved by BN-PAGE (4–20%) in its non-denatured (native, no SDS) or partially denatured (0.1% SDS) state and visualized by typhoon fluorescence scanning. a Cy5-labeled surface form of the indicated mP2X2 proteins in their native or partial SDS denatured forms as indicated. b TagRFP fluorescence of the BN-PAGE gel shown in a. The number of protomers included in the respective bands is schematically indicated at the right margin. c, d Subcellular distribution and function of mouse P2X2-StrepII-His-RFP receptor construct transiently expressed in HEK293 cells. c Confocal laser scanning microscopy shows plasma membrane bound TagRFP fluorescence, which is also highlighted by the fluorescence intensity diagram along a cross section through the cell. d Representative current trace recorded by the whole-cell patch-clamp technique of a HEK293 cell transiently expressing the mouse P2X2-StrepII-His-RFP receptor construct. The horizontal black bar indicates the duration of application of the agonist 2-meS-ATP (10 µM). Scale bar: c = 10 µm

---
shown by Cy5 fluorescence (Fig. 1a). The red fluorescence of TagRFP of the corresponding fused constructs is shown (Fig. 1b). All TagRFP fused mP2X2R constructs were found to be expressed at the plasma membrane and were present in their native/non-denatured form as trimers.

The mP2X2-StrepII-His-TagRFP construct is transiently expressed in HEK293 cells and shows a plasma membrane-bound TagRFP fluorescence as well (Fig. 1c). Figure 1d displays a representative current trace of a HEK293 cell expressing the mP2X2-StrepII-His-TagRFP of a whole-cell measurement by patch-clamp electrophysiology in which the mP2X2R-mediated current response was induced by 2-meS-ATP, demonstrating that the mP2X2-StrepII-His-TagRFP receptor is functional.

Figure 2a shows the schematic illustration of the Tg(RP23-333M22P2X2-StrepHis-TagRFP) transgene, which
Fig. 2 Transgenic P2X2 mice line C57BL/6 J-Tg(RP23-333M22P2X2-StrepHis-TagRFP). a Schematic illustration of a region of the mouse chromosome 5 indicating the position of the origin of BAC clone RP23-333M22 (vertical red line). The BAC clone RP23-333M22 containing the full-length P2RX2 gene (red box) is shown below. The P2RX2 gene is shown with its 11 exons. The StrepII-His-TagRFP encoding sequence (StrepII-His-TagRFP cassette) was inserted directly upstream of the stop codon (exon 11). b–j Confocal laser scanning microscopy of TagRFP fluorescence and TagRFP-/neuronal co-immunostaining. b–d show an overlay of confocal TagRFP fluorescence imaging and transmitted light imaging. Images of a b native dorsal root ganglion, c–g cultured DRG neurons (e–g PFA fixed), and h–i PFA-fixed cryosections of the dentate gyrus/CA4 region of the hippocampus of an adult C57BL/6 J-Tg(RP23-333M22P2X2-StrepHis-TagRFP) mouse. b Native TagRFP-fluorescence (red) of a crush preparation of a dorsal root ganglion. c, d Native TagRFP-fluorescence (red, arrows) of cultured DRG neurons (2 days in vitro (DIV 2)). e, f TagRFP and MAP2 co-immunostaining (overlay, TagRFP red, MAP2 green; antibodies (ab)) of PFA-fixed cultured DRG neurons (DIV 2). Only a fraction of MAP2-positive DRG neurons do co-express the P2X2-StrepHis-TagRFP transgene (arrows). g TagRFP and MAP2 co-immunostaining (overlay, TagRFP red, MAP2 green) of PFA-fixed cultured DRG neurons of a wild-type C57BL/6 J mouse (littermate control). Scale bars: h, c, e, h = 50 μm; d, f, g, i, j = 10 μm

drives the P2X2-TagRFP expression under control of the promoter of the P2RX2 gene. In the C57BL/6 J-Tg(RP23-333M22P2X2-StrepHis-TagRFP) BAC-transgenic mice, we were able to detect TagRFP fluorescence in dorsal root ganglia (DRG) neurons, and we could visualize the receptor in cerebral structures, including hippocampal tissues. After pronuclear injection of the modified BAC Tg(RP23-452G4P2RY1-TagRFP), eight founder lines were obtained, and offspring were analyzed regarding the TagRFP fluorescence within the hippocampus. Only one line shows a strong fluorescence intensity and is used for further breeding (Suppl. Figure 1; line G503 was chosen for further breeding). Expression of P2X2 fusion receptor is demonstrated in a large number of cells of an entire DRG (squeeze preparation) of hemizygous transgenic mice by native TagRFP fluorescence (Fig. 2b). In cultured DRG neurons, a small number of cells only (small arrows) exhibit fluorescent receptors, most pronounced after 2 days in culture (Fig. 2c). The localization of the receptor at this stage of cultivation shows predominantly in intracellular membranes (Fig. 2d; thick arrow) and appears infrequently on the cell surface, indicating an active regulation of surface expression. Co-immunolabeling with antibodies against TagRFP and against the neuronal marker MAP2 confirms the expression in neurons (Fig. 2e, f), whereas no TagRFP fluorescence could be detected in littermate controls (WT) (Fig. 2g). In tissue sections, we could observe the expression of the fusion-receptor only by signal amplification, taking advantage of antibodies specific for TagRFP. This prevented the tracking of living cells in tissue sections of P2X2R-TagRFP mice by native TagRFP fluorescence. Using TagRFP-immunostaining, P2X2-TagRFP expression is found in neurons in the dentate gyrus within the hippocampus (Fig. 2h, i) of transgenic (TG) mice, but not in littermate controls (WT) (Fig. 2j).

Furthermore, we found P2X2-TagRFP expression in the brain stem (Fig. 3a–c) in the medulla in the area postrema as well as in fibers within the nucleus tractus solitarius, in the cerebellum (Fig. 3d–f), where most calbindin-positive cells expressed P2X2-TagRFP and in the superficial laminae of the dorsal horn in the spinal cord (Fig. 3g–i).

P2Y1R transgenic mouse model

We also generated C57BL/6 J-Tg(RP23-452G4P2RY1-TagRFP) BAC-transgenic mice-expressing TagRFP under control of the regulatory elements of the P2RY1 gene to advance the morphological identification and functional characterization of P2Y1R-expressing cells. Figure 4a shows the schematic illustration of the Tg(RP23-452G4P2RY1-TagRFP) transgene, which drives the TagRFP expression under control of the promoter of the P2RY1 gene. After pronuclear injection of the modified BAC Tg(RP23-452G4P2RY1-TagRFP), eight fertile founder lines were obtained, and offspring were analyzed regarding the TagRFP fluorescence within the hippocampus. The hippocampus was selected as a particularly suitable region for a screening analysis of different founder lines, since the expression of the P2Y1R in this CNS region has been repeatedly demonstrated in various studies (for instance, see [36, 37]). However, great differences appeared in the intensity of native TagRFP fluorescence in different founder lines and their offspring. Five lines show viable native TagRFP fluorescence, and one of them shows particularly strong fluorescence intensity and is chosen for further breeding and characterization (Suppl. Figure 2; line T933 was chosen for further breeding). Please note that the expression pattern is conserved among the different founder lines that showed native TagRFP fluorescence (Suppl. Figure 2c, e, f, g, h), which suggests that the TagRFP expression is independent from the position of integration within the genome.

In these P2Y1R BAC-transgenic reporter mice, we were able to detect TagRFP fluorescence in several cerebral tissues, including hippocampal neurons and astrocytes. We examined the expression levels of native TagRFP fluorescence in P2Y1R-expressing neurons and astrocytes (Fig. 4b–j) and also enhanced the visibility of TagRFP-expressing cells by using TagRFP-specific immunocytochemistry (Fig. 5a–l).

 Springer
As shown in Fig. 4, native TagRFP fluorescence is found in cells within the hippocampus, i.e., without the need of antibody-dependent signal enhancement. Figures 4b, d, e, and g show TagRFP fluorescence in the soma...
and the entire processes of hippocampal neurons (thick arrows) located in the dentate gyrus and CA1/2 regions at the border of the molecular and polymorphic layer to the granular layer of the dentate gyrus (e.g., Fig. 4b–d), suggesting that the TagRFP reporter protein may allow for tracking the projections of P2Y₁R-expressing neurons (see also Fig. 6a–c). Additionally, also the TagRFP expression on GFAP-positive astrocytes is observed (Fig. 4b–g, thin arrows). Some TagRFP-positive cells could be identified as neurons based on co-localization with multiple neuronal markers. In an additional analysis, an in vitro lesion model for mechanical injury was used [38]. We observe the outgrowth of TagRFP- and GFAP-co-expressing astrocytes in the lesion area in hippocampal neuron-glia mixed cell cultures after a scratch lesion (Fig. 4h–j). These astrocytes develop fibers in
the lesion area, and also the presence of completely (cell body, processes) double-labeled cells is observed (Fig. 4h–j, thin arrows). This indicates a strong P2Y1R expression during astroglial proliferation or migration processes and thus may support the findings of previous studies about a role of P2Y1Rs in proliferation and regeneration [12–16].

In a next step of our investigations, we extended our P2Y1R expression analysis to further brain regions. TagRFP immunostaining and hence P2RY1 expression are detected in (i) the mitral cell layer and at the border between the external plexiform layer and the glomerular layer of the olfactory bulb, but no co-localization with GFAP co-immunofluorescence; (ii) the ventral tegmental area (VTA) (Fig. 5d–f); (iii) the Purkinje cell layer of the cerebellum (Fig. 5g–i); and (iv) the laminae I-II and with less intensity in laminae III-V of the dorsal horn of the spinal cord (Fig. 5j–l). The arrows show neurons with strong MAP2/TagRFP co-staining. Scale bars: c, f, i, l = 50 µm
Loss of fluorescence over time

At the beginning of the P2Y1R project, different transgenic founder lines were investigated and analyzed with respect to expression in the hippocampus. As detailed above, a comparable qualitative expression pattern in glial cells and neurons could be demonstrated within the different lines (offspring of different founder lines, c.f. Suppl. Figure 2), but the intensity of fluorescence differed between the lines. The line with the strongest expression (in terms of the strongest TagRFP fluorescence intensity) was selected for further breeding, but an intermittently occurring low fluorescence was observed in some transgenics during breeding. In the further course of breeding, the initially quite strong fluorescence intensity decreased from generation to generation. This is illustrated in Fig. 6. While in the first generations a pronounced TagRFP fluorescence in cell bodies and processes of hippocampal neurons were detected (Fig. 6a), the fluorescence became successively weaker in the course of further generations (Fig. 6b, c) until after about 2 years of breeding; no fluorescence is detectable in neuronal processes; and also the cell bodies show only a weak residual labeling (Fig. 6d). It was also observed that over time, the fluorescence became increasingly granular in the cell bodies.

Discussion

Transgenic mice as tools to analyze the P2R expression

Our transgenic models In the studies described here, we have generated (i) C57BL/6 J BAC transgenic mice that express the P2X2R subunits as fluorescent fusion protein (P2X2-TagRFP) controlled by its own promoter and (ii) a BAC P2Y1R TagRFP reporter mouse expressing a TagRFP reporter for the P2RY1 gene expression to identify cells in situ carrying P2X2Rs or expressing the P2YR1 gene, respectively. We show that the targeted receptors are expressed in different cells and tissues of the transgenic mice lines. In our C57BL/6 J BAC transgenic mice, we were able to demonstrate expression of the P2X2R in a subset of DRG neurons, the brain stem, the hippocampus, as well as on Purkinje neurons of the cerebellum. The expression pattern on DRG neurons and in the specified locations of the CNS, such as the hippocampus, was recently confirmed by other P2X2R transgenic mouse lines detailed below [39, 40]. However, it should be reemphasized here that the weak fluorescence intensity in our P2X2R-TagRFP mouse and the therefore necessary use of anti-TagRFP immunostaining and subsequent signal amplification have precluded tracking of living cells or identifying them in sections for targeted examination, e.g., by patch-clamp electrophysiology.

Our P2Y1R reporter mice confirmed the widespread expression of the P2RY1 gene in the CNS that was previously indicated by RT-PCR, in situ hybridization and immunocytochemistry [e.g. 12–15, 37, 41–43]. However, TagRFP reporter expression indicates for the first time P2Y1R expression in mouse Purkinje cells, which so far has only been described in rats [41] and in the human brain [37]. The TagRFP and thus P2Y1R gene expression within the olfactory bulb are in agreement with the known expression pattern of the P2Y1R in the olfactory bulb as assessed by functional analysis [43]. We found P2Y1R gene expression in dopaminergic neurons of the VTA, which fits well to functional data showing that stimulation of the P2Y1R expressed in the VTA resulted in the increased release of glutamate [44] and neuronal fiber growth [45].
Other transgenic models  A BAC transgenic tool with which to study P2X4R-expressing cells is P2RX4 reporter mice Tg(P2RX4-tdTomato)1Khakh expressing the red fluorescent protein tdTomato under the control of the P2X4 locus by insertion into exon 1 of the P2RX4 gene to replace the endogenous initiation of translation codon in the BAC clone RP23-44806 [46]. The pattern of tdTomato expression in the brain of these mice matched P2X4 mRNA distribution as described in the Allen Brain Atlas database. Furthermore, it highlights the role of well-characterized reporter mice to reveal new insights into purinergic receptor roles as the discovery of feeding-related regulation of presynaptic P2X4R responses in the hypothalamic arcuate nucleus.

The P2RX7 reporter mouse line Tg(P2RX7-EGFP)FY174Gsat/ Mmcd from the aforementioned GENSAT project express an enhanced green fluorescent protein (EGFP) reporter gene driven by the regulatory sequences of the P2RX7 gene on the BAC clone RP23-181F3. The reporter gene was inserted at the initiating ATG codon of the first coding exon of the P2RX7 gene and is followed by a polyadenylation sequence. These mice were used as a tool to show that expression of the receptor is selectively increased in CA1 pyramidal and dentate granule neurons, as well as in microglia in mice that developed a status epilepticus after intra-amygdala injection of kainic acid [47]. However, these GENSAT P2X7 GFP-reporter mice were recently shown to exhibit prominent ectopic expression [48], which makes the evaluation of the P2X7 expression by these mice at least difficult or even error-prone.

In another study, BAC transgenic mice were generated for the in vivo analysis of the P2X7R expression [48]. Within the CNS, the P2X7R plays a role in several brain diseases such as epilepsy and Alzheimer’s disease, and since its identification, researchers still debate whether P2X7Rs are expressed in neurons and in other types of brain cells, although an increasing number of studies suggest its presence in neurons [49]. To resolve this issue and to provide a model for in vivo analysis of P2X7Rs P2X7 BAC transgenic mice were generated that overexpress GFP-tagged P2X7 under the control of a BAC-derived mouse P2X7 gene (P2rx7) promoter [48]. Under physiological conditions in the CNS, the P2X7R was shown to be predominantly located in microglia and oligodendrocytes a. After neural tissue damage or following status epilepticus, no upregulation of P2X7 protein in neurons was observed. Thus, the authors concluded that the reported P2X7-dependent neuronal damage may be the consequence of the pronounced manifestation of microglia activation rather than the direct activation of neuronal P2X7Rs [48].

Another reporter mouse line developed as a knock-in mouse that is expressing Cre recombinase in a P2X2-dependent fashion and subsequently crossed with a cre-sensitive tdTomato mouse line [39]. Moreover, similar to our findings, this mouse line shows reporter expression in neurons in the dentate gyrus within the hippocampus. Another mouse line indicates the expression of P2X2Rs in hippocampal neurons, using the genetically encoded fluorescent indicator for Ca<sup>2+</sup> YC3.1 as a fusion P2X2Rs in hippocampal neurons, recombinated into the BAC vector RP23-221H5 [40]. With this Tg(Camk2a-P2rx2/YC3.1)21Khakh, mouse line-specific P2X2-YC expression was observed within mossy fibers, particularly in the stratum lucidum of the hippocampus, generating a tool to drive neurotransmitter release selectively from the mossy fiber pathway. This fluorescently tagged receptor expressed in hippocampal neurons has already been used successfully to track its activation in vivo [50], and these mice may be useful to get a deeper insight into mossy fiber physiology.

Additionally, a P2RY1 knockout with lacZ reporter (P2RY1<sup>Δmi(KOMP)Vlcg</sup>) produced by Regeneron Pharmaceuticals (Tarrytown, NY, USA) for the knockout mouse project (KOMP) at the University of California is meanwhile available and was recently used to study P2Y<sub>1</sub>R expression in the developing cochlea [51]. It was shown that burst firing of mouse inner hair cells prior to hearing onset requires P2RY1 autoreceptors expressed by inner supporting cells and that purinergic signaling in cochlear supporting cells regulates hair cell excitability by volume control of the extracellular space [51].

Taken together, our P2X2R and P2Y<sub>1</sub>R mouse models and other P2R transgenic models designed for visualizing the P2R expression have advanced the understanding of purinergic transmission, but BAC transgenic models appeared not always to be straightforward.

Limitations and pitfalls in expression analysis with BAC transgenic mice

BAC transgenic mice offer some advantages over conventional knock-in approaches. The enhancement of expression as a result of the random integration of multiple copies of the transgene, avoiding integration site artifacts and using the endogenous regulatory elements of the genes of interest and not least the comparatively fast generation of these transgenic mice (at least at that time), is certainly of great advantage. This has already been described frequently [22]. On the other hand, although limitations have been described (for instance see [22]), reports on various other problems are sparse. One of the most frequently described issues in BAC transgenesis is the unwanted effects caused by integration of the large transgene in another gene. This can, for example, lead to a functional knockout of the affected gene or cause a changed expression pattern of the gene [22]. This may lead to misinterpretation regarding the effect of the transgene expression. In order to rule out that phenotypes are due to
positioned effects or disruption of endogenous genes at the integration site, it is generally recommended to analyze at least two transgenic mouse lines for a given transgene with their random and unique genomic integration sites of the BAC transgene. Only reproducible phenotypes between the different lines should be unambiguously attributed to the transgene expression [22].

In the present paper, we have taken the opportunity to share also openly our own experiences and problems for the benefit of other scientists. Even though the figures above are showing promising results and have brought in part the hoped-for gain in knowledge regarding the expression analysis of P2X2 or P2Y1 receptors, the projects have subsequently encountered considerable challenges.

In the P2X2R project, the native TagRFP fluorescence was weak and hardly detectable, and even after using using anti-TagRFP immunostaining, additional signal amplification systems were necessary to detect mP2X2R-TagRFP expression. Thus, except for the primarily cultured DRG neurons, it was not possible to reliably detect the expression of the mP2X2-TagRFP transgene in living cells from analyzed tissue. The preceding comprehensive and diligent analyses of P2X2 constructs in heterologous expression systems (Xenopus oocytes and HEK293 cells), confirming that TagRFP fusion did not markedly affect assembly, expression and function, were not able to predict strong native fluorescence in P2X2-expressing cells in the transgenic animal when expression is driven by the endogenous regulatory elements of the P2RX2 gene. Of course, this is not generally unexpected, but once again, this shows that results from overexpression experiments may not reflect the situation in vivo. For this reason alone, projects to generate (BAC) transgenic mice always remain risky.

One problem that occurred in the P2Y1R project in the further course of breeding is the intermittently occurring low fluorescence observed in some transgenics during breeding and the successively weaker fluorescence in the course of further generations until after about 2 years of breeding no fluorescence was detectable in neuronal processes, and also the cell bodies showed only a weak residual labeling (c.f. Figure 6). Also, over time, the fluorescence became increasingly granular in the cell bodies. As a likely explanation, the initial strong fluorescence was caused by the integration of several copies of the transgene possibly at more than one site into the genome. During the course of breeding, individual copies of the transgene were lost, resulting in a decrease of the expression of the TagRFP reporter. In the SOD1 mouse model of amyotrophic lateral sclerosis, it was already shown that a sporadic loss of transgene copy number can occasionally occur, probably by internal recombinations. The sporadic deletion of integrated transgene copies in the course of the breeding clearly reduced transgene expression as compared to expression in preceding generations prior to deletion [52]. Conventional PCR used for genotyping is not able to detect the number of copies, so that a loss of individual copies or the loss at one of multiple integration sites during the breeding process remains undetected. Thus, intermittent southern blot analysis or quantitative PCR techniques are suitable to quantify the number of copies and can help to detect this problem early and to adjust the breeding process if necessary. Monitoring of the BAC transgene copy number should be performed on a regular basis in the course of breeding to evaluate transgene expression and to confirm stability of integrations and germline transmission across successive generations.

In the future, however, BAC recombineering may no longer be the first choice for genome editing, but transgenes will directly enter endogenous loci through more versatile and adaptable nuclease-mediated genome-editing methods such as the CRISPR/Cas technology, which have developed rapidly over the last decade.

**Conclusion**

Our P2X2R and P2Y1R mouse models and other P2R transgenic models designed for visualizing the P2R expression have advanced the knowledge toward a deeper understanding of P2R expression and purinergic transmission, but BAC transgenic models appeared not always to be straightforward and permanent reliable.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11302-021-09792-9.

**Acknowledgement** We thank Katrin Becker, Helga Sobottka, Anne-Kathrin Krause (Rudolf Boehm Institute of Pharmacology and Toxicology) and Ursula Brahm (Institute of Pharmacology, RWTH Aachen University) for their excellent technical assistance.

We also thank Professor HaiHong Wang (Department of Physiology Medical School, Tongji University, Shanghai; China) for their support in patch-clamp electrophysiology.

**Authors’ contributions** G.S., H.F., and R.H. designed the study; M.G., M.S., J.G., S.M.S., T.N., F.W., Z.G., R.J., and D.H. carried out the experiments; C.L., P.I., G.S., H.F., and R.H. designed and supervised experiments; C.L., P.I., G.S., H.F., and R.H. analyzed data; M.G., H.F., and R.H. drafted the manuscript and all authors revised/reviewed the manuscript and approved the final version for publication.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This study was financially supported by the Deutsche Forschungsgemeinschaft (DFG) within the delocalized Research Unit FOR 748 “Neuronal and glial P2 receptors; molecular basis and functional significance” (subproject 3: FR 1253/3–1; FR 1253/3–2; SCHM 536/8–1, SCHM 536/8–2).

© Springer
Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval This article does not contain any studies with human participants. Animal experiments were in compliance with the European Union legislation (Directive 86/609/EEC), approved by the Committee of Animal Care and Use of the relevant local governmental body and in accordance with the European Federation of European Laboratory Animal Science Associations (FELASA) standards, and were approved by the relevant regulatory authorities (Leipzig: T21/13; T05/16; Aachen: Xenopus laevis oocytes for heterologous protein expression: 9.93.2.10.44.07.104; mice: 10857 A4).

Informed consent This article does not contain any studies with human participants. Accordingly, no informed consent (consent to participate or consent for publication) was required.

Conflicts of interest

Conclusions All authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304
2. Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. Nature 442(7102):527–532
3. Surprenant A, North RA (2009) Signaling at purinergic P2X receptors. Annu Rev Physiol 71:333–359
4. Kaczmarek-Hajek K, Lorinczi E, Hausmann R, Nicke A (2012) Molecular and functional properties of P2X receptors-recent progress and persisting challenges. Purinergic Signal 8:375–417
5. Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178(3):489–514. http://doi.org/10.1111/bph.15299
6. Vulečanová L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R (1996) Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci USA 93(15):8063–8067
7. Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, Ruan HZ, Ma B, Yip P, Nunn P, McMahon SB, Burnstock G, Ford AP (2005) P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol 567:621–639
8. Jarvis MF (2010) The neural-glial purinergic receptor ensemble in chronic pain states. Trends Neurosci 33(1):48–57
9. Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schoneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE (2020) Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 177(11):2413–2433
10. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Norden P, Norden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817):202–207
11. Jacobson KA, Müller CE (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology 104:31–49
12. Franke H, Verkhratsky A, Burnstock G, Illes P (2012) Pathophysiology of astroglial purinergic signalling. Purinergic Signal 8(3):629–657
13. Franke H, Illes P (2014) Nucleotide signaling in astroglia. Neurosci Lett 565:14–22
14. Franke H, Illes P (2014) Pathological potential of astroglial purinergic receptors. Adv Neurobiol 11:213–256
15. Heine C, Sygnecka K, Franke H (2016) Purines in neurite growth and astroglia activation. Neuropharmacology 104:255–271
16. Verkhratsky A, Nedergraad M (2018) Physiology of Astroglia. Physiol Rev 98(1):239–389
17. Miras-Portugal MT, Queipo MJ, Gil-Redondo JC, Ortega F, Gomez-Villafuertes R, Gualix J, Delicado EG, Perez-Sen R (2019) P2X receptor interaction and signalling cascades in neuroprotection. Brain Res Bull 151:74–83
18. Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7(7):575–590
19. Inoue K (2021) Nociceptive signaling of P2X receptors in pain states. Purinergic Signal 17(1):41–47. http://doi.org/10.1007/s11302-020-09743-w
20. Zhang X, Li G (2019) P2Y receptors in neuropathic pain. Pharmacol Biochem Behav 186:172788
21. Jacobson KA (2021) Tribute to Prof. Geoffrey Burnstock: transition of purinergic signaling to drug discovery. Purinergic Signal 17(1):3–8. http://doi.org/10.1007/s11302-020-09717-y
22. Yang XW, Gong S (2005) An overview on the generation of BAC transgenic mice for neuroscience research. Curr Protoc Neurosci Chapter 5:Unit 5 2 10
23. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Jovy A, Leblanc G, Hatten ME, Hentiz N (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425(6961):917–925
24. Polz M, Klapperstuck M, Kendzierski T, Dettos-Dassan S, Panning A, Schmalzing G, Markwardt F (2015) Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors. Pflügers Arch 467(10):2121–2140
25. Hausmann R, Bahrenberg G, Kuhlmann D, Schumacher M, Braam U, Bieler D, Schlusche I, Schmalzing G (2015) A hydrophobic residue in position 15 of the rP2X3 receptor slows desensitization and reveals properties beneficial for pharmacological analysis and high-throughput screening. Neuropharmacology 79:603–615
26. Becker D, Woltersdorf R, Boldt W, Schmitz S, Braam U, Schmalzing G, Markwardt F (2008) The P2X7 carboxyl tail is a regulatory module of P2X7 receptor channel activity. J Biol Chem 283(37):25725–25734
27. Haeger S, Kuzmin D, Dettos-Dassan S, Lang N, Kilb M, Tsetlin V, Betz H, Laube B, Schmalzing G (2010) An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors. Nat Struct Mol Biol 17(1):90–98
28. Fallah G, Romer T, Dettos-Dassan S, Braam U, Markwardt F, Schmalzing G (2011) TMEM16A(a) /anoctamin-1 shares a
homodimeric architecture with CLC chloride channels. Mol Cell Proteomics 10(2):M110

29. Himmel HM, Kiss T, Borvendeg SJ, Gillen C, Illes P (2002) The arginine-rich hexapeptide R4W2 is a stereoselective antagonist at the vanilloid receptor 1: a Ca2+ imaging study in adult rat dorsal root ganglion neurons. J Pharmacol Exp Ther 301(3):981–986

30. Rubini P, Pagel G, Mehrs H, Marquardt P, Riedel T, Illes P (2014) Functional P2X7 receptors at cultured hippocampal astrocytes but not neurons. NaunynSchmiedebergs Arch Pharmacol 387(10):943–954

31. Osoegawa K, Tateno M, Woon PY, Frengen E, Mammoser AG, Catanese JJ, Hayashizaki Y, de Jong PJ (2000) Bacterial artificial chromosome libraries for mouse sequencing and functional analysis. Genome Res 10(1):116–128

32. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33(4):e36

33. Vintersten K, Testa G, Naumann R, Anastassiadis K, Stewart AF (2008) Bacterial artificial chromosome transgenesis through pronuclear injection of fertilized mouse oocytes. Methods Mol Biol 415:83–100

34. Shaner NC, Lin MZ, McKeown MR, Steinbach PA, Hazelwood KL, Davidson MW, Tsien RY (2008) Improving the photostability of bright monomeric orange and red fluorescent proteins. Nat Methods 5(6):545–551

35. Merzlyak EM, Goedhart J, Scherbo D, Bulina ME, Shcheglov AS, Fradkov AF, Gaintzeva A, Lukyanov KA, Lukyanov S, Gadella TW, Chudakov DM (2007) Bright monomeric red fluorescent protein with an extended fluorescence lifetime. Nat Methods 4(7):555–557

36. Tonazzini I, Trincavelli ML, Storm-Mathisen J, Martinelli C, Bergersen LH (2007) Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus. Eur J Neurosci 26(4):890–902

37. Moore D, Chambers J, Waldvogel H, Faull R, Emson P (2000) Regional and cellular distribution of the P2Y1 purinergic receptor in the human brain: striking neuronal localisation. J Comp Neurol 421(3):374–384

38. Cragnolini AB, Montenegro G, Friedman WJ, Masco DH (2018) Brain-region specific responses of astrocytes to an in vitro injury and neurotrophins. Mol Cell Neurosci 88:240–248

39. Kim SH, Bahia FK, Patil M, Sutton S, Sowells I, Hadley SH, Kollarik M, Taylor-Clark TE (2020) Development of a mouse reporter strain for the purinergic P2X2 receptor. eNeuro 7(4):ENEURO.0203-20.2020. http://doi.org/10.1523/ENEURO.0203-20.2020

40. Haustein MD, Kracun S, Lu XH, Shih T, Jackson-Weaver O, Tong X, Xu J, Yang XW, O’Dell TJ, Marvin JS, Ellisman MH, Bushong EA, Looger LL, Khakh BS (2014) Conditions and constraints for astrocyte calcium signaling in the hippocampal mossy fiber pathway. Neuron 82(2):413–429

41. Amadio S, Vacca F, Martorana A, Sansacari G, Volonte C (2007) P2Y1 receptor switches to neurons from glia in juvenile versus neonatal rat cerebellar cortex. BMC Dev Biol 7:77

42. Simoes AP, Silva CG, Marques JM, Pochmann D, Porciuncula LO, Ferreira S, Oses JP, Beleza RO, Real JJ, Kofalvi A, Bahr BA, Lerma J, Cunha RA, Rodrigues RJ (2018) Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation. Cell Death Dis 9(3):297

43. Fischer T, Rotermund N, Lohr C, Hirnet D (2012) P2Y1 receptor activation by photolysis of caged ATP enhances neuronal network activity in the developing olfactory bulb. Purinergic Signal 8(2):191–198

44. Krügel U, Schraft T, Regenthal R, Illes P, Kittner H (2004) Purinergic modulation of extracellular glutamate levels in the nucleus accumbens in vivo. Int J Dev Neurosci 22(7):565–570

45. Heine C, Sygnecka K, Scherf N, Grohmann M, Bräsigk A, Franke H (2015) P2Y(1) receptor mediated neuronal fibre outgrowth in organotypic brain slice co-cultures. Neuropsycharmacology 93:252–266

46. Xu J, Bernstein AM, Wong A, Lu XH, Khoja S, Yang XW, Davies DL, Micevych P, Sofroniew MV, Khakh BS (2016) P2X4 receptor reporter mice: sparse brain expression and feeding-related presynaptic facilitation in the arcuate nucleus. J Neurosci 36(34):8902–8920

47. Jimenez-Pacheco A, Diaz-Hernandez M, Arribas-Blazquez M, Sanz-Rodriguez A, Olivos-Ore LA, Artalejo AR, Alves M, Letavic M, Miras-Portugal MT, Conroy RM, Delanty N, Farrell MA, O’Brien DF, Bhattacharya A, Engel T, Henschall DC (2016) Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and glisiss in experimental temporal lobe epilepsy. J Neurosci 36(22):5920–5932

48. Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Risseeck B, Saul A, Bruzzzone S, Engel T, Jooss T, Krautloher A, Schuster S, Magnus T, Stadelmann C, Sirko S, Koch-Nolte F, Eulenburg V, Nicke A (2018) Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife 7:36217

49. Sperlagh B, Illes P (2014) P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci 35(10):537–547

50. Richter E, Shigetomi E, Khakh BS (2011) Neuronal P2X2 receptors are mobile ATP sensors that explore the plasma membrane when activated. J Neurosci 31(46):16716–16730

51. Babola TA, Kersbergen CJ, Wang HC, Bergles DE (2020) Purinergic signaling in cochlear supporting cells reduces hair cell excitability by increasing the extracellular space. Elife 9:e52160

52. Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, Heiman-Patterson TD (2004) Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res 130(1–2):7–15

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.